
A six-case briefing on the week's material AI, tech-platform, telecom, and pharma litigation developments, with procedural posture, business impact, precedent value, and next checkpoints.
| Sector | Parties | Forum / docket | Event in the window | Next public checkpoint |
|---|---|---|---|---|
| AI | Anthropic PBC v. U.S. Department of War | U.S. District Court for the Northern District of California, 3:26-cv-01996 | Judge Rita Lin ruled against the Pentagon's supply-chain-risk designation on August 28. 12 | Any post-ruling motion or appeal; a related Washington, D.C. designation case remains pending. |
| AI | Druyan-Sagan Associates Inc. v. Luma AI Inc. | U.S. District Court for the Central District of California, 2:26-cv-09474 | Complaint filed August 25 over an audio clip from Cosmos used in an advertisement. 3 | Luma's response and the court's first scheduling step; a hearing date has not been publicly reported. |
| Tech / consumer protection | Meta Platforms and U.S. states | Specific court and case number were not reported in the accessible account | Meta agreed on August 26 to a settlement with maximum exposure of $16.68 billion after trial proceedings over youth safety, consumer disclosures, and children's data. 4 | Court approval and the settlement's operational changes and payment schedule. |
| Tech / competition | Barry Rodger and UK app developers v. Google | London's Competition Appeal Tribunal; case number was not reported | Google agreed on August 27 to a proposed £260 million settlement, subject to tribunal approval. 5 | Competition Appeal Tribunal approval. |
| Tech / telecom | Asus v. AT&T, Verizon, T-Mobile, Ericsson and Nokia | Texas federal court; case number was not reported | A jury ruled on August 26 that Asus's three asserted patents were invalid and rejected its related FRAND claims. 6 | Post-trial motions or an appeal, if filed. |
| Pharma / biotech | Vertex Pharmaceuticals Inc. v. Lupin Ltd. | U.S. District Court for the District of Delaware; case number was not reported | Judge Stephanos Bibas rejected Vertex's patent suit on August 24 because Lupin's proposed generic lacked the concentration covered by the asserted patents. 7 | The public record's next remedy, post-trial, or appeal entry. |
courtlistener.com
This story was produced automatically by a channel. One sentence is all it takes for Neodrop to keep producing for you.